Summary: For the first nine months of 2008 the Pharmexa Group generated revenues and other operating income of DKK 16,138 thousand and a net loss of DKK 117,095 thousand. Research and development costs totalled DKK 116,307 thousand. The Pharmexa Group retains its financial forecast for the full year.